MedTrace Logo

Safety and Efficacy of NVXT Solution in Mild-to-Moderate Fungal Infection of the Toe Nail

NCT02343627 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 47

Last updated 2018-09-19

Study results available
· View outcomes & findings →

Summary

This study will examine the safety, tolerability and efficacy of NVXT in a new formulation in patients with mild-to-moderate fungal infection of the toe nail.

Conditions

  • Onychomycosis

Interventions

DRUG

NVXT Solution

NVXT Solution, applied to infected toe nails and 0.5 mm of adjacent skin once daily for 60 days.

DRUG

Vehicle of test product

Vehicle of test product applied to infected toe nails and 0.5 mm of adjacent skin once daily for 60 days.

Sponsors & Collaborators

  • Sun Pharmaceutical Industries, Inc.

    lead INDUSTRY

Principal Investigators

  • Taro Pharmaceuticals USA · Taro Pharmaceuticals USA Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-12-31
Primary Completion
2016-01-31
Completion
2016-01-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02343627 on ClinicalTrials.gov